Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Recruiting

Phase 1

BXCL501Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Sponsor:

BioXcel Therapeutics Inc

Code:

NCT05025605

Conditions

Schizophrenia

Schizo-Affective Disorder

Schizophreniform; Schizophrenic

Bipolar Disorder I

Bipolar Disorder II

Eligibility Criteria

Sex: All

Age: 10 - 17

Healthy Volunteers: Not accepted

Interventions

BXCL501 80 Micrograms

Placebo Film

BXCL501 120 Micrograms

BXCL501 60 Micrograms

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-30. This information was provided to ClinicalTrials.gov by BioXcel Therapeutics Inc on 2024-11-12.